Submit Manuscript  

Article Details

Measurement of Cdk4 Kinase Activity Using an Affinity Peptide-Tagging Technology

[ Vol. 3 , Issue. 1 ]


Jinzi J. Wu, Donna R. Yarwood, Bhabatosh Chaudhuri, Lionel Muller, Mauro Zurini and Mathew A. Sills   Pages 27 - 36 ( 10 )


Cyclin dependent kinases such as Cdk4 are involved in the control of cell cycle progression, and misregulation of Cdk4 has been implicated in many types of cancers. In the present study, we report the development of a novel homogeneous assay using an affinity peptide-tagging technology for rapidly discovering Cdk4 inhibitors. The DNA sequence encoding a streptavidin recognition motif, or StrepTag (AWRHPQFGG), was cloned and expressed at the C-terminus of a fusion protein of a 152-amino acid hyperphosphorylation domain (Rb152) of the retinoblastoma protein (Rb) linked to GST at the N-terminus. This affinity peptide-tagged protein (GST-Rb152-StrepTag), which contains the two known phosphorylation sites of Rb, specifically phosphorylated by Cdk4 in vivo, was used as a substrate in the current in vitro kinase assay. After phosphorylation, scintillation proximity assay (SPA) scintillant beads coated with streptavidin were added. Radiolabeled GST-Rb152-StrepTag was brought in close proximity to the SPA sci ntillant beads through the interaction between StrepTag and streptavidin, resulting in the emission of light from beads. By applying the affinity peptide-tagging technology, we have eliminated the separation and wash steps which are normally required in a radioactive filtration assay. Therefore, this homogeneous method is simple, robust, and highly amenable to high-throughput screening of Cdk4-specific inhibitors. Furthermore, the affinity peptide tagging technique reported here is a simple, generic method that can be applied to many recombinant proteins for the development of kinase and protein-protein interaction assays.


Cdk4 kinase actiity, Strep tag, yclin dependent kinases, Scintillation proximity assay, Filter binding assay, Phosphorylation, GST Rb152, Biotinylated peptide


Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, 556 Morris Avenue, LSB 1113, Summit, NJ 07901, USA

Read Full-Text article